Abstract
Hantaan virus (HTNV) is the etiological pathogen of hemorrhagic fever with renal syndrome in East Asia. There are currently no effective therapeutics approved for HTNV and other hantavirus infections. We found that griffithsin (GRFT), an algae-derived lectin with broad-spectrum antiviral activity against various enveloped viruses, can inhibit the growth and spread of HTNV. In vitro experiments using recombinant vesicular stomatitis virus (rVSV) with HTNV glycoproteins as a model revealed that the GRFT inhibited the entry of rVSV-HTNV-G into host cells. In addition, we demonstrated that GRFT prevented authentic HTNV infection in vitro by binding to the viral N-glycans. In vivo experiments showed that GRFT partially protected the suckling mice from death induced by intracranial exposure to HTNV. These results demonstrated that GRFT can be a promising agent for inhibiting HTNV infection.
Introduction
Hantaan virus (HTNV) is the primary cause of Hemorrhagic Fever with Renal Syndrome (HFRS), a severe disease endemic to East Asia with mortality rates reaching 15%. Despite its significant public health impact, there are currently no FDA-approved vaccines or specific antiviral therapeutics for HTNV. This study investigates the potential of Griffithsin (GRFT), a protein derived from red algae, as a broad-spectrum antiviral treatment. GRFT is a lectin known for its ability to bind specifically to sugar molecules on the surface of enveloped viruses, effectively "trapping" them and preventing host cell entry.
Mechanism of Action: The Sugar Trap
HTNV is an enveloped virus wrapped in a lipid membrane studded with glycoproteins (Gn and Gc). These glycoproteins are heavily coated in $N$-glycans (polysaccharides), which typically assist in protein folding and immune evasion. GRFT acts as a molecular glue by binding to these high-mannose oligosaccharides.
By targeting specific "sweet spots" on the viral surface, GRFT prevents the virus from attaching to or fusing with host cell membranes. Site-directed mutagenesis revealed that while no single sugar site is solely responsible for entry, a cluster of sites—N347, N399, and N928—serves as the primary target for GRFT's inhibitory action.
Experimental Methodology
The researchers employed a comprehensive experimental framework to validate GRFT's efficacy:
- Pseudovirus Modeling: Used recombinant Vesicular Stomatitis Virus (rVSV) expressing HTNV glycoproteins (rVSV-HTNV-G) to safely study viral entry.
- Authentic Virus Validation: Confirmed findings using wild-type HTNV (strain 76-118) in BSL-3 facilities.
- In Vivo Testing: Evaluated survival rates in a suckling mouse model following intracranial exposure.
- Competitive Inhibition: Demonstrated that GRFT's activity is carbohydrate-specific by pre-treating the protein with mannose.
Key Results
The study yielded several significant findings regarding GRFT's potency and safety:
- Potent Inhibition: GRFT inhibited HTNV pseudovirus entry with an $IC_{50}$ as low as 0.03 $\mu$g/ml. For authentic HTNV, the $IC_{50}$ ranged from 12.87 to 20.75 $\mu$g/ml.
- Enhanced Survival: In the suckling mouse model, untreated mice faced 100% mortality. However, mice treated with 100 $\mu$g/ml of GRFT achieved an 80% survival rate.
- Pan-Hantaviral Activity: GRFT showed inhibitory effects against a broad range of hantaviruses, including those causing Hantavirus Pulmonary Syndrome (HPS) like Andes and Sin Nombre viruses.
- Safety Profile: Cytotoxicity assays confirmed that GRFT does not negatively impact cell viability at therapeutic concentrations.
Discussion and Future Directions
While these results are promising, several hurdles remain. The use of suckling mice is a necessary but imperfect proxy for human HFRS. Furthermore, the current study focused on pre-incubation or simultaneous administration; future work must determine the "therapeutic window" for treating established infections.
Because GRFT is already in Phase I clinical trials for other applications (such as HIV prevention), its safety profile in humans is encouraging. Optimization of systemic delivery mechanisms will be crucial for developing GRFT into a viable clinical treatment for HTNV and other hantavirus infections.
Summary updated